Copper‐CX‐5461: A novel liposomal formulation for a small molecule rRNA synthesis inhibitor
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Controlled Release"
DOI: 10.1016/j.jconrel.2018.07.025
Abstract: ABSTRACT CX‐5461 is currently in Phase I/II clinical trials for advanced hematologic malignancies and triple negative or BRCA‐deficient breast cancer. The compound is currently administered to patients intravenously (i.v.) at low pH (3.5) due to… read more here.
Keywords: novel; copper; formulation; copper 5461 ... See more keywords